Previous 10 | Next 10 |
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration PR Newswire CRANFORD, N.J. , Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a lat...
2024-02-23 16:38:15 ET More on Citius Pharmaceuticals Citius resubmits marketing application for lymphoma therapy Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citiu...
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences PR Newswire CRANFORD, N.J. , Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company de...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update PR Newswire Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial C...
2024-02-14 08:45:40 ET More on Citius Pharmaceuticals Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citius Pharmaceuticals Read the full article on Seeking Alpha ...
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma PR Newswire FDA acceptance of the completed resubmission package and issuance of a Pres...
Asics Corporation ADR (ASCCY) is expected to report for quarter end 2023-12-31 W. P. Carey Inc. REIT (WPC) is expected to report $1.16 for Q4 2023 Core Scientific, Inc. (CORZQ) is expected to report for Q4 2023 Essent Group Ltd. (ESNT) is expected to report $1.59 for Q4 2023 SAAB ...
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors PR Newswire Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024 CRANFORD, N.J. , Jan. 23, 2024 ...
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters PR Newswire Topline results expected 2Q 2024 Study enrolled a total of 241 patients; 109 catheter failures observed First-and-only antibi...
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update PR Newswire Mino-Lok ® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 ...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...